Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury

American Journal of Gastroenterology

Volumn 111, Issue 7, 2016, Pages 958-965

  Hillman, Luke ^a   Gottfried, Michelle ^b   Whitsett, Maureen ^a   Rakela, Jorge ^c   Schilsky, Michael ^d   Lee, William M ^e   Ganger, Daniel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANABOLIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTITHYROID AGENT; CARDIAC AGENT; CATHA EDULIS EXTRACT; CEPHALOSPORIN; COTRIMOXAZOLE; DISULFIRAM; DOXYCYCLINE; HALOTHANE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; KAVA; NITROFURANTOIN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENYTOIN; PRESCRIPTION DRUG; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; TOXIN; TUBERCULIN; UNINDEXED DRUG; USNIC ACID; VALERIAN; ALKALINE PHOSPHATASE;

ACUTE LIVER FAILURE; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALTERNATIVE MEDICINE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIETARY SUPPLEMENT; FEMALE; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOXIC HEPATITIS; ADVERSE EFFECTS; BLOOD; CHEMICAL AND DRUG INDUCED LIVER INJURY; GRAFT SURVIVAL; LIVER; LIVER FAILURE, ACUTE; LIVER FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES; STATISTICS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ALKALINE PHOSPHATASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLEMENTARY THERAPIES; FEMALE; GRAFT SURVIVAL; HUMANS; LIVER; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; UNITED STATES;

EID: 84962691349     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.114     Document Type: Article

References (35)

1. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
2. Bjornsson ES, Bergmann OM, Bjornsson HK et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. 1425.e1-3; quiz e19-20.
3. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
4. Chalasani N, Bonkovsky HL, Fontana R et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7.
5. Chalasani N, Fontana RJ, Bonkovsky HL et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. 1934.e1-4.
6. Reuben A, Koch DG, Lee WM et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.
7. Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
8. Goldberg DS, Forde KA, Carbonari DM et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 2015; 148: 1353-61. e3.
9. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013; 37: 3-17.
10. Administration USFaD. Guidance for Industry A Dietary Supplement Labeling Guide: Chapter IV. Nutritional Labeling. In (FDA) USFaDA (ed), 2005.
11. Harkey MR, Henderson GL, Gershwin ME et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73: 1101-6.
12. Lai V, Smith A, Thorburn D et al. Severe hepatic injury and adulterated Chinese medicines. BMJ 2006; 332: 304-5.
13. Wai CT, Tan BH, Chan CL et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27: 465-74.
14. Office UGA. Herbal Dietary Supplements: Examples of Deceptive or Questionable Marketing Practices and Potentially Dnagerous Advice; 26 May 2010.
15. Lindstrom AOC, Lynch ME, Blumenthal M. Herb supplement sales increase 5.5% in 2012: herbal supplement sales rise for 9th consecutive year; turmeric sales jump 40% in natural channel. HerbalGram 2013, 60-5.
16. Radimer K, Bindewald B, Hughes J et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004; 160: 339-49.
17. Bailey RL, Gahche JJ, Lentino CV et al. Dietary supplement use in the United States, 2003-2006. J Nutr 2011; 141: 261-6.
18. Navarro VJ, Barnhart H, Bonkovsky HL et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399-408.
19. Fontana RJ, Watkins PB, Bonkovsky HL et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
20. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
21. Kamath PS, Kim WR. Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
22. Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol 2011; 57: 213-29.
23. Aleo MD, Luo Y, Swiss R et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014; 60: 1015-22.
24. Urban TJ, Shen Y, Stolz A et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22: 784-95.
25. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34: 123-33.
26. Foureau DM, Walling TL, Maddukuri V et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015; 180: 40-51.
27. Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015; 35: 1801-8.
28. Oda S, Matsuo K, Nakajima A et al. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol Lett 2015; 241: 60-70.
29. Lo Re V 3rd, Haynes K, Forde KA et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model. Clin Gastroenterol Hepatol 2015; 13: 2360-8.
30. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999; 74: 443-7.
31. Tarn DM, Karlamangla A, Coulter ID et al. A cross-sectional study of provider and patient characteristics associated with outpatient disclosures of dietary supplement use. Patient Educ Couns 2015; 98: 830-6.
32. Kemper KJ, Amata-Kynvi A, Dvorkin L et al. Herbs and other dietary supplements: healthcare professionals' knowledge, attitudes, and practices. Altern Ther Health Med 2003; 9: 42-9.
33. Cellini M, Attipoe S, Seales P et al. Dietary supplements: physician knowledge and adverse event reporting. Med Sci Sports Exerc 2013; 45: 23-8.
34. MedWatch. The FDA Safety Information and Adverse Event Reporting Program: Reporting Serious Problems to FDA. 20 January 2015 [cited 22 September 2015]; Available from http://www.fda.gov/Safety/MedWatch/ HowToReport/default.htm.
35. United States National Library of Medicine National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 23 June 2015 [cited 2015; Available from http://livertox.nih.gov/.